This article is more than 5 years old. Information may no longer be current.
Five ophthalmology clinical trial updates you might have missed
Click Here to Manage Email Alerts
Ophthalmic clinical trials of products for diabetic macular edema and Leber’s hereditary optic neuropathy, as well as geographic atrophy and pain and inflammation in cataract surgery, all moved forward in the month of August.
Here are the top five clinical trial updates for the month as reported on Healio.com/OSN:
1. Luminate meets primary endpoint in phase 2b trial for DME
Allegro Ophthalmics announced the DEL MAR phase 2b stage 2 clinical trial met its primary endpoint for Luminate in the treatment of diabetic macular edema. Read more.
2. Clearside completes enrollment in trial of noninfectious uveitis treatment
The phase 3 PEACHTREE trial evaluating the efficacy of CLS-TA for suprachoroidal administration in patients with macular edema associated with noninfectious uveitis completed its patient enrollment. Read more.
3. Enrollment completed in Leber’s hereditary optic neuropathy trial
GenSight Biologics announced that enrollment in the phase 3 RESCUE trial of GS010 to treat Leber’s hereditary optic neuropathy has been completed. Read more.
4. Apellis’ geographic atrophy treatment meets phase 2 endpoint
APL-2 met its primary endpoint in a phase 2 trial in patients with geographic atrophy associated with age-related macular degeneration. Read more.
5. First patients enrolled in EGP-437 trial
EyeGate Pharmaceuticals’ phase 2b trial of EGP-437 to treat pain and inflammation in cataract surgery patients enrolled its first patient. Read more.